Phil leads the firm’s healthcare investing, leveraging his 20 years of experience advancing Dartmouth College’s innovation ecosystem. He currently leads Borealis’ investments in Adimab, Avedro, Avitide, Compass Therapeutics, Evox Therapeutics, Orbit Discovery and Vets First Choice. Phil also led the firm’s prior investments in GlycoFi (acquired by Merck & Co.) and M2S (acquired by AIG Altaris Health Partners).

Phil joined Borealis from Dartmouth College’s Tuck School of Business, where he was the founding Executive Director of the Center for Private Equity and Entrepreneurship. Phil remains an adjunct member of Tuck’s faculty teaching venture capital and entrepreneurship topics. Phil was previously a trustee of the Dartmouth Regional Technology Center.

Prior to joining the Tuck faculty, Phil held senior strategy and business development roles at a privately-held application software company. Earlier in private legal practice, he counseled technology startups, Fortune 500 companies and foreign governments on sensitive trade, tax, and investment matters.

Phil received an A.B. degree from Dartmouth College, a J.D. from the University of Virginia School of Law and a M.B.A. (with High Distinction) from the Tuck School of Business at Dartmouth.